Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL2166181 | 0.89 | FFAR3 (0.37) | CA2 | |
| SCHEMBL28627981 | 0.89 | CA2 (0.30) | CA2 | |
| Formic Acid SCHEMBL2168609 | 0.89 | CA2 (0.30) | CA2 | |
| SCHEMBL2948137 | 0.88 | CA2 (0.33) | CA2 | |
| Propionic Acid SCHEMBL2168558 | 0.84 | FFAR3 (0.48) | — | |
| SCHEMBL2952770 | 0.84 | PTGS1 (0.30) | — | |
| SCHEMBL29257630 | 0.83 | — | — | |
| SCHEMBL4501254 | 0.78 | — | — | |
| SCHEMBL22749161 | 0.78 | — | — | |
| SCHEMBL1865621 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109326773-B | Electrode active material, battery electrode and semiconductor nano battery | 天极新能源实业（深圳）有限公司 | 2021-12-28 | — | — | CN | claimed |
| EP-2685540-B1 | NON-AQUEOUS ELECTROLYTE AND NON-AQUEOUS-ELECTROLYTE SECONDARY BATTERY USING SAME | MITSUBISHI CHEM CORP (JP) | 2021-03-10 | — | — | EP | claimed |
| US-20170149088-A1 | METHOD OF MANUFACTURING NONAQUEOUS SECONDARY BATTERY | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2017-05-25 | — | — | US | claimed |
| WO-2016009263-A1 | METHOD OF MANUFACTURING NONAQUEOUS SECONDARY BATTERY | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | WO | claimed |
| US-8440349-B2 | Nonaqueous electrolyte solution and lithium secondary battery using same | UBE INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | claimed |
| EP-1772924-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY | UBE INDUSTRIES (JP) | 2013-04-10 | — | — | EP | claimed |
| US-8053109-B2 | Non-aqueous electrolyte secondary battery | SANYO ELECTRIC CO., LTD. (JP) | 2011-11-08 | — | — | US | claimed |
| US-20100239919-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | UBE INDUSTRIES, LTD. (JP) | 2010-09-23 | — | — | US | claimed |
| US-7754380-B2 | Nonaqueous electrolyte solution and lithium secondary battery using same | UBE INDUSTRIES, LTD. (JP) | 2010-07-13 | — | — | US | claimed |
| US-20090130566-A1 | NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | SANYO ELECTRIC CO., LTD. (JP) | 2009-05-21 | — | — | US | claimed |
| US-6479191-B1 | COMPRISING A NON-AQUEOUS SOLVENT, AN ELECTROLYTE SALT DISSOLVED THEREIN AND AT LEAST ONE ALKYNE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2002-11-12 | — | — | US | claimed |
| US-20250233206-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-07-17 | — | — | US | disclosed |
| US-12315883-B2 | Non-aqueous electrolyte solution and non-aqueous electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-05-27 | — | — | US | disclosed |
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| US-20230395857-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-12-07 | — | — | US | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| US-6479191-B1 | COMPRISING A NON-AQUEOUS SOLVENT, AN ELECTROLYTE SALT DISSOLVED THEREIN AND AT LEAST ONE ALKYNE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2002-11-12 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | CA2 1585/4885KDM4E 2501/4885CYP3A4 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.